Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-02-08
2005-02-08
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C424S138100, C424S141100, C424S143100, C424S152100, C424S178100, C424S179100
Reexamination Certificate
active
06852318
ABSTRACT:
The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue.
REFERENCES:
patent: 5536814 (1996-07-01), Ruoslahti et al.
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5627263 (1997-05-01), Ruoslahti et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5866540 (1999-02-01), Jonczyk et al.
patent: 5922676 (1999-07-01), Pasqualini et al.
patent: 6177542 (2001-01-01), Ruoslahti et al.
patent: 0906919 (1999-04-01), None
patent: WO 9315203 (1993-08-01), None
patent: WO 9514714 (1995-01-01), None
patent: WO9514714 (1995-06-01), None
patent: WO 9604304 (1996-02-01), None
patent: WO9710507 (1997-03-01), None
patent: WO 9733887 (1997-09-01), None
patent: WO9810795 (1998-03-01), None
patent: WO9913329 (1999-03-01), None
Gallin et al (Inflammation:Basic Principles and Clinical Correlates, Raven Press, New York, p. 552), 1988.*
Thorpe (Monoclonal Antibodies in Biological and Clinical Applications, Pinchera et al., eds., pp. 475-506), 1988.*
Guo et al (Cancer Research, 1997, 57:1737-1742).*
Scott et al (J. Invest. Derm., 1997, 108:147-153).*
Varner, J.A. et al., “Tumor Angiogenesis and the Role of Vascular Cell Integrin αvβ3,”Important Advances in Oncology, 1996, pp. 69-87, Lippincott-Raven Publishers, Philadelphia, PA.
Varner, J.A. et al., “Integrins and Cancer,”Current Opinion in Cell Biology, Oct. 1996, pp. 724-730.
Varner, J.A. et al., “Antagonists of Vascular Cell Integrin α5β1 Inhibit Angiogenesis,” [reprint]Circulation, Oct. 27, 1998, p. 4166.
Thorpe inMonoclonal Antibodies in Biological and Clinical Applications, Pinchera et al., eds, 1995, pp. 475-506
Gallin et al., in Inflammation: Basic Principles and Clinical Correlates, Raven Press, NY, 1988, p. 552.
Takada et al. (1988) “Extracellular Matrix Receptors, ECMRII and ECMRI, for Collagen and Fibronectin correspond to VLA-2 and VLA-3 in the VLA Family of Heterodimers,” J. Cell. Biochem. 37:385-393.
Takada et al. (1987) “Fibronectin receptor structures in the VLA family of heterodimers,” Nature 326:607-609.
Eliccs et al. (1991) “Receptor Functions for the Integrin VLA-3: Fibronectin, Collagen, and Laminin Binding are Differentially Influenced by Arg-Gly-Asp Peptide and by Divalent Cations,” J. Cell Biol. 112:169-181.
Masumoto & Hemler (1993) “Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS1/fibronectin and to vascular cell adhesion molecule-1,” J. Biol. Chem. 268:228-234.
Zhang et al. (1993) “The αvβ 1 Integrin Functions as a Fibronectin Receptor But Does Not Support Fibronectin Matrix Assembly and Cell Migration on Fibronectin.” J. Cell Biol. 122:235-242.
Ruegg et al. (1992) “Role of integrin α4β7/α4βP in Lymphocyte Adherence to Fibronectin and VCAM-1 and in Homotypic Cell Clustering,” J. Cell Biol. 117:179-189.
Orlando and Cheresh (1991) “Arginine-Glycine-Aspartic Acid Binding Leading to Molecular Stabilization Between Integrin αvβ3and Its Ligand,” J. Biol. Chem. 266:19543-19550.
Suehiro et al. (1997) “Fibrinogen is a Ligand for Integrin α5β1on Endothelial Cells,” J. Biol. Chem. 272:5360-5366.
Suehiro et al. (2000) “Fibrinogen Binds to Integrin α5β1via the Carboxyl-Terminal RGD site of the Aα-chain,” J. Biochem. 128:705-710.
Felding Haberman et al. (1997) “A Single Immunoglobulin-like Domain of the Human Neural Cell Adhesion Molecule L1 Supports Adhesion by Multiple Vascular and Platelet Integrins.” J. Cell Biol. 139:1567-1581.
Silletti et al. (2000) “Plasmin Sensitive Dibasic Sequences in the Third Fibronectin-like Domain of L-cell Adhesion Molecule (CAM) Facilitate Homomultimerization and Concomitant Integrin Recruitment,” J. Cell Biol. 149:1485-102.
Rehn et al. (2001) “Interaction of endostatin with integrins implicated in angiogenesis” Proc. Natl. Acad. Sci. 98:1024-1029.
Carlson et al. (2001) “Direct Cell Adhesion to the Angiopoietins Mediated by Integrins,” J. Biol Chem. 276:26516-26525.
Marcinkiewicz et al.(1999) “Structural and Functional Characterization of EMF10, a Heterodimeric Disintegrin fromEristocophis macmahoniVenom that Selectively Inhibits α5β1Integrin” Biochem. 38:13302-13309.
Wierzbicka-Potynowski et al. (1999) “Structural requirements of Echistatin for the Recognition of αvβ3and α5β1Integrins,” J. Biol. Chem. 274:37809-14.
Yi and Ruoslahti (2001) “A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis,” Pro. Natl. Acad. Sci. 98:620-624.
Varner et al. (1995) “Integrin α5β1Expression Negatively Regulates Cell Growth: Reversal by Attachment to Fibronectin,” Mol. Biol. Cell 6:725-740.
Morla et al. (1994) “Superfibronectin is a functionally distinct form of fibronectin,” Nature 367:193-198.
Kim et al. (2000) “Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1with the Central Cell-Binding Domain of Fibronectin,” Am. J. Pathol. 156:1345-1362.
Pasqualini et al. (1996) “A polymeric form of fibronectin has antimetastatic effects against multiple tumor types,” Nature Med. 2:1197-1203.
Kumar et al. (1997) “Biochemical Characterization of the Binding of Echistatin to Integrin αvβ3Receptor,” J. Pharmacol. Experimen. Therap. 283:843-853.
Nowlin et al. (1993) “A Novel Cyclic Pentapeptide Inhibits α4β1 and α5β1 Integrin-mediated Cell Adhesion,” J. Biol. Chem. 268:20352-20359.
Takagi et al. (1997) “Structural Interlock between Ligand-Binding Site and Stalk-Like Region of β1 Integrin Revealed by a Monoclonal Antibody Recognizing Conformation-Dependent Epitope,” J. Biochem. 121:914-921.
Kim et al. (2002) “Inhibition of endothelial cell survival and angiogenesis by protein kinase A,” J. Clin. Invest. 110:933-941.
Clark et al. (1982) “Blood vessel fibronectin increases in conjunction ith endothelial cell proliferation and capillary ingrowth during wound healing,” J Invest Dermatol. Nov;79(5):269-76.
Castellani et al. (1994) “The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis,” Int J Cancer. 59:612-618.
Neri et al. (1997) “Targeting by a affinity-matur
The Regents of the University of California
Townsend and Townsend / and Crew LLP
Ungar Susan
LandOfFree
Methods for detecting and inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for detecting and inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for detecting and inhibiting angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3445162